Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck...

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) is overexpressed in colorectal and head and neck squamous cell carcinoma (SCCHN), correlating with poor prognosis.
• EGFR-targeted monoclonal antibodies (mAbs) like cetuximab show limited efficacy (10-20%) in patients, suggesting immune mechanisms contribute to response.
• Cetuximab resistance involves EGFR degradation, potentially increasing tumor antigen presentation for T cell recognition.

Purpose of the Study:

• To identify and characterize novel T cell epitopes of EGFR for enhanced immunotherapy.
• To develop combinatorial strategies involving EGFR-specific mAbs and T cell-based therapies.
• To improve the efficacy of EGFR-targeted cancer treatments.

Main Methods:

• Identification of a novel immunogenic wild-type peptide, EGFR853-861, and modification for enhanced HLA-A*0201 binding.
• Assessment of cross-reactivity with HER2861-869.
• Evaluation of EGFR853-861-specific cytotoxic T lymphocyte (CTL) recognition of SCCHN cells after cetuximab treatment.
• Quantification of EGFR853-861-specific CTLs in SCCHN patients versus healthy controls.

Main Results:

• A novel, immunogenic EGFR-encoded CTL epitope (EGFR853-861) was identified, capable of stimulating cross-reactive CTLs.
• Cetuximab treatment enhanced EGFR853-861-specific CTL recognition of SCCHN cells by promoting EGFR degradation.
• Elevated levels of EGFR853-861-specific CTLs were observed in SCCHN patients compared to healthy controls.

Conclusions:

• A novel, immunogenic EGFR-encoded CTL epitope can be incorporated into cancer vaccines.
• This epitope holds potential for combinatorial immunotherapy with EGFR-specific mAbs in cancer patients.
• The findings support T cell-based immunotherapy as a strategy to enhance the efficacy of EGFR-targeted therapies.